Sex, Gender, and FDA Tobacco Policy
FDA should consider differences in how tobacco products are marketed to and used by people of different biological sexes and gender identities as it develops
Michael Posey
May 31, 2023
FDA should consider differences in how tobacco products are marketed to and used by people of different biological sexes and gender identities as it develops
In a trial of 608 U.K. participants with chronic pain from nonmalignant causes, a group-based intervention significantly reduced opioid use but not affecting perceived pain
Following events such as nonfatal drug overdoses, use of medications for treating opioid use disorder (OUD) differed based on race and ethnic background, according to
In 3 pragmatic clinical trials of medication for opioid use disorder (MOUD), the risk of overdose was elevated in the 24 weeks after randomization for
Between 2017 and 2021, the number of clinicians with 30-patient buprenorphine waivers under the Drug Addiction Treatment Act (DATA) increased in the U.S. Still, nearly
Only 1 in 5 patients initiating monthly buprenorphine therapy in Jan. 2016 through Oct. 2022 continued treatment for opioid use disorder for at least 180
“The consequences of meeting the national goal of no more than 81,000 fatal drug overdoses per year by 2025 are highly consequential,” write staff members
Comorbid posttraumatic stress disorder (PTSD) and substance-use disorders should be managed using a combination approach, including alcohol-targeted pharmacotherapies and trauma-focused behavioral therapies that lead to
The gap between opioid use disorder and buprenorphine dispensing trends to youth aged 19 years or younger indicated that many individuals are receiving the help
FDA yesterday approved daprodustat tablets (Jesduvroq, GlaxoSmithKline) as the first oral treatment for anemia caused by chronic kidney disease for adults who have been receiving